Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guerini, V.
Right arrow Articles by Poletti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guerini, V.
Right arrow Articles by Poletti, A.
[Cancer Research 65, 5445-5453, June 15, 2005]
© 2005 American Association for Cancer Research

Endocrinology

The Androgen Derivative 5{alpha}-Androstane-3ß,17ß-Diol Inhibits Prostate Cancer Cell Migration Through Activation of the Estrogen Receptor ß Subtype

Vittoria Guerini1, Daniela Sau1, Eugenia Scaccianoce1, Paola Rusmini1, Paolo Ciana3, Adriana Maggi3, Paolo G.V. Martini4, Benita S. Katzenellenbogen4, Luciano Martini1, Marcella Motta1,2 and Angelo Poletti1

1 Institute of Endocrinology, 2 Center for Endocrinological Oncology, and 3 Department of Pharmacological Sciences, University of Milan, Italy; and 4 Department of Molecular and Integrative Physiology, University of Illinois, Urbana-Champaign, Illinois

Requests for reprints: Angelo Poletti, Institute of Endocrinology, via Balzaretti 9-20133 Milan, Italy. Phone: 390-25031-8215; Fax: 390-25031-8204; E-mail: angelo.poletti{at}unimi.it.

Prostate cancer growth depends, in its earlier stages, on androgens and is usually pharmacologically modulated with androgen blockade. However, androgen-ablation therapy may generate androgen-independent prostate cancer, often characterized by an increased invasiveness. We have found that the 5{alpha}-reduced testosterone derivative, dihydrotestosterone (the most potent natural androgen) inhibits cell migration with an androgen receptor–independent mechanism. We have shown that the dihydrotestosterone metabolite 5{alpha}-androstane-3ß,17ß-diol (3ß-Adiol), a steroid which does not bind androgen receptors, but efficiently binds the estrogen receptor ß (ERß), exerts a potent inhibition of prostate cancer cell migration through the activation of the ERß signaling. Very surprisingly, estradiol is not active, suggesting the existence of different pathways for ERß activation in prostate cancer cells. Moreover, 3ß-Adiol, through ERß, induces the expression of E-cadherin, a protein known to be capable of blocking metastasis formation in breast and prostate cancer cells. The inhibitory effects of 3ß-Adiol on prostate cancer cell migration is counteracted by short interfering RNA against E-cadherin. Altogether, the data showed that (a) circulating testosterone may act with estrogenic effects downstream in the catabolic process present in the prostate, and (b) that the estrogenic effect of testosterone derivatives (ERß-dependent) results in the inhibition of cell migration, although it is apparently different from that linked to estradiol on the same receptor and may be protective against prostate cancer invasion and metastasis. These results also shed some light on clinical observations suggesting that alterations in genes coding for 3ß-hydroxysteroid dehydrogenases (the enzymes responsible for 3ß-Adiol formation) are strongly correlated with hereditary prostate cancer.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. McIntyre, P. W. Kantoff, M. J. Stampfer, L. A. Mucci, D. Parslow, H. Li, J. M. Gaziano, M. Abe, and J. Ma
Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2233 - 2236.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Miyamoto, Z. Yang, Y.-T. Chen, H. Ishiguro, H. Uemura, Y. Kubota, Y. Nagashima, Y.-J. Chang, Y.-C. Hu, M.-Y. Tsai, et al.
Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals
J Natl Cancer Inst, April 4, 2007; 99(7): 558 - 568.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
L. Bonaccorsi, D. Nosi, M. Muratori, L. Formigli, G. Forti, and E. Baldi
Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines
J. Mol. Endocrinol., January 1, 2007; 38(1): 51 - 66.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. R. Bauman, S. Steckelbroeck, D. M. Peehl, and T. M. Penning
Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and Prostate Cancer
Endocrinology, December 1, 2006; 147(12): 5806 - 5816.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.